Jan 9 (Reuters) - Novo Nordisk:
* OZEMPIC® APPROVED IN CANADA FOR THE TREATMENT OF ADULTS WITH TYPE 2 DIABETES
* SAYS OZEMPIC DEMONSTRATED CLINICALLY MEANINGFUL IMPROVEMENTS IN BLOOD SUGAR AND BODY WEIGHT VERSUS COMPARATORS Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.